Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
25.00    0.00 (0.00%)
Bid:
24.00
Ask:
26.00
Spread: 2.00 (8.333%)
Market Cap: £27.00m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Trading Statement

2 Nov 2017 07:00

RNS Number : 3058V
Elektron Technology PLC
02 November 2017
 

Elektron Technology plc

("Elektron", the "Group" or the "Company")

 

Trading Update

 

Elektron Technology plc (AIM: EKT), the global technology group, is pleased to provide an update on trading for the third quarter ended 31 October 2017.

Sales

Group trading was strong in Q3 with sales increasing 34% compared to the same period last year to £8.6m (2017: £6.4m). Year to date sales have increased by 15% to £22.9m (2017: £19.9m).

Bulgin achieved record quarterly sales of £7.8m in Q3, 37% higher than the same period last year (2017: £5.7m) following successful manufacturing scale-up to convert the unprecedented order demand in H1 into sales. The board expects that Bulgin sales will revert to more normal levels through Q4.

 

Sales £m

Unaudited

Unaudited

Q3 2018

Q3 2017

YTD 2018

YTD 2017

Bulgin

7.8

5.7

20.3

17.4

IMC (Queensgate and Elektron Eye Technology)

0.7

0.7

2.3

2.3

Checkit

0.1

0.3

0.2

 

Total

 

8.6

 

6.4

 

22.9

 

19.9

 

Orders

Group order intake remains well ahead of prior year, with all business segments demonstrating growth.

Bulgin and IMC orders are both 20% above prior year levels year to date.

Checkit has continued to build recurring revenue streams and total contracted annual recurring revenue (including forthcoming contracted installations) now stands at £0.7m, compared with £0.3m at the same time last year (+133%).

Cash

Group net cash was approximately £3.0m at 31 October 2017 (31 July 2017: £2.0m; 31 January 2017: £1.0m) following the initial proceeds from the Sheen Instruments disposal of £1.1m in October. The net cash position has also been impacted by investment in working capital of approximately £0.4m as a result of the strong trading performance in this quarter.

John Wilson, Chief Executive Officer of Elektron, said:

"Q3 trading has been strong. The Board now expects full year performance to be ahead of its previous expectations."

Enquiries:

 

Elektron Technology plc 

www.elektron-technology.com

 

+44 (0) 1223 371 000

John Wilson - Chief Executive Officer

 

Andy Weatherstone - Chief Financial Officer & Company Secretary

 

 

 

finnCap (Nominated Adviser & Broker)

+44 (0)20 7220 0500

Ed Frisby / Scott Mathieson - Corporate Finance

 

Abigail Wayne - Corporate Broking

 

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

Notes to Editors

Elektron conceives designs and markets innovative engineered products and services for businesses that connect, monitor and control. We have a multi skilled team of engineers, software and product line specialists based in Cambridge focused on the opportunities created by global trends in the following areas:

 

- Demand for ubiquitous power and data: Bulgin

- New waves of "aware" business applications: Checkit

- The effect of ageing on sight: Elektron Eye Technology

- Growth in high precision manufacture: Queensgate

 

Cautionary statement

This financial information has been prepared only for the shareholders of Elektron as a whole and its sole purpose and use is to assist shareholders to exercise their governance rights. Elektron and its Directors and employees are not responsible for any other purpose or use or to any other person in relation to this report.

The report contains indications of likely future developments and other forward-looking statements that are subject to risk factors associated with, among other things, the economic and business circumstances occurring from time to time in the countries, sectors and business segments in which the Group operates. Key risks and their mitigation have not changed materially in the period from those disclosed on pages 12 to 14 of the annual financial statements for the year ended 31 January 2017.

These and other factors could adversely affect the Group's results, strategy and prospects. Forward-looking statements involve risks, uncertainties and assumptions. They relate to events and/or depend on circumstances in the future which could cause actual results and outcomes to differ materially from those currently anticipated. No obligation is assumed to update any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBUBDBCSGBGRB
Date   Source Headline
26th Jan 20167:00 amRNSDirectorate Change
20th Jan 20163:22 pmRNSHolding(s) in Company
25th Nov 20157:00 amRNSProduct Launch
24th Nov 20153:21 pmRNSHolding(s) in Company
10th Nov 20157:00 amRNSTrading Update
19th Oct 20153:41 pmRNSDerivative Claim - Update
5th Oct 20157:00 amRNSProduct Launch
28th Sep 20157:00 amRNSDirector's Dealing
14th Sep 20154:12 pmRNSDirector's dealing
10th Sep 20157:00 amRNSDirectorate Changes
10th Sep 20157:00 amRNSHalf Yearly Report
30th Jul 20154:45 pmRNSResult of AGM
23rd Jul 20159:00 amRNSTrading Update
22nd Jul 20157:00 amRNSDerivative claim - update
16th Jul 20154:09 pmRNSDerivative Claim - Update
8th Jul 20153:16 pmRNSLapse of Options
6th Jul 20153:49 pmRNSNotice of AGM
26th Jun 20154:00 pmRNSHolding(s) in Company
18th Jun 20158:50 amRNSDerivative Claim - Update
12th Jun 20154:42 pmRNSAnnual Report and Financial Statements
30th Apr 20157:00 amRNSFinal Results
27th Apr 20155:35 pmRNSHolding(s) in Company
7th Apr 20151:41 pmRNSHolding(s) in Company
12th Feb 20157:00 amRNSYear end trading update
28th Jan 201512:45 pmRNSDerivative Claim - Further Update
24th Nov 20147:00 amRNSTrading update
2nd Oct 20147:00 amRNSDerivative Claim - Update
31st Jul 20146:06 pmRNSResult of AGM
31st Jul 20147:00 amRNSAGM Statement
25th Jul 201411:15 amRNSDirector/PDMR Shareholding
17th Jul 201412:15 pmRNSResult of Open Offer
9th Jul 20148:00 amRNSNotice of AGM
25th Jun 20145:42 pmRNSHolding(s) in Company
23rd Jun 20147:00 amRNSPlacing and Proposed Open Offer
23rd Jun 20147:00 amRNSUnaudited full year results
20th Jun 20147:00 amRNSConclusion of Strategic Alternatives Process
17th Jun 20147:00 amRNSStatement regarding Elektron Technology plc
2nd Jun 20145:33 pmRNSForm 8 (OPD) Microgen plc
2nd Jun 201412:35 pmRNSForm 8.3 - [Microgen Plc]
27th May 20142:10 pmRNSStatement re Elektron Technology Plc
21st May 20149:00 amRNSResponse to Microgen
20th May 201412:39 pmRNSFurther Statement Re Elektron Technology Plc
20th May 201410:20 amRNSStatement re Elektron Technology
13th May 20143:20 pmRNSStrategic Alternatives Process Update
29th Apr 201410:09 amRNSHolding(s) in Company - Replacement
25th Apr 20142:03 pmRNSForm 8.3 - Elektron Technology Plc
25th Apr 20141:45 pmRNSForm 8 (DD) - [Elektron Technology PLC]
23rd Apr 20145:32 pmRNSForm 8.3 - [Elektron Technology Plc]
23rd Apr 20143:22 pmRNSForm 8.3 - [Elektron Technology]
23rd Apr 20143:15 pmPRNForm 8.3 - Elektron Technology Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.